Published in J Clin Invest on July 01, 2004
PPAR gamma and human metabolic disease. J Clin Invest (2006) 3.83
Interference with PPAR gamma function in smooth muscle causes vascular dysfunction and hypertension. Cell Metab (2008) 2.17
Cullin-3 regulates vascular smooth muscle function and arterial blood pressure via PPARγ and RhoA/Rho-kinase. Cell Metab (2012) 1.99
Hypotension, lipodystrophy, and insulin resistance in generalized PPARgamma-deficient mice rescued from embryonic lethality. J Clin Invest (2007) 1.85
Protecting against vascular disease in brain. Am J Physiol Heart Circ Physiol (2011) 1.66
Maternal PPAR gamma protects nursing neonates by suppressing the production of inflammatory milk. Genes Dev (2007) 1.62
PPARgamma in human and mouse physiology. Biochim Biophys Acta (2007) 1.58
Interference with PPARgamma signaling causes cerebral vascular dysfunction, hypertrophy, and remodeling. Hypertension (2008) 1.55
Endothelium-specific interference with peroxisome proliferator activated receptor gamma causes cerebral vascular dysfunction in response to a high-fat diet. Circ Res (2008) 1.48
Increased energy expenditure, dietary fat wasting, and resistance to diet-induced obesity in mice lacking renin. Cell Metab (2007) 1.39
Ligand-activated peroxisome proliferator-activated receptor-gamma protects against ischemic cerebral infarction and neuronal apoptosis by 14-3-3 epsilon upregulation. Circulation (2009) 1.30
Dominant-negative loss of PPARgamma function enhances smooth muscle cell proliferation, migration, and vascular remodeling. Arterioscler Thromb Vasc Biol (2009) 1.23
Pioglitazone-induced reductions in atherosclerosis occur via smooth muscle cell-specific interaction with PPAR{gamma}. Circ Res (2010) 1.22
PPARγ regulates resistance vessel tone through a mechanism involving RGS5-mediated control of protein kinase C and BKCa channel activity. Circ Res (2012) 1.11
Mouse Models of Lipodystrophy Key reagents for the understanding of the metabolic syndrome. Drug Discov Today Dis Models (2007) 1.10
Peroxisome proliferator-activated receptors, metabolic syndrome and cardiovascular disease. Future Cardiol (2010) 1.06
Endothelial and vascular muscle PPARgamma in arterial pressure regulation: lessons from genetic interference and deficiency. Hypertension (2009) 1.06
Bioinformatic analysis of gene sets regulated by ligand-activated and dominant-negative peroxisome proliferator-activated receptor gamma in mouse aorta. Arterioscler Thromb Vasc Biol (2009) 1.05
Quantitative trait loci for individual adipose depot weights in C57BL/6ByJ x 129P3/J F2 mice. Mamm Genome (2006) 1.05
The adipose renin-angiotensin system modulates systemic markers of insulin sensitivity and activates the intrarenal renin-angiotensin system. J Biomed Biotechnol (2006) 1.04
PPARgamma and its ligands: therapeutic implications in cardiovascular disease. Clin Sci (Lond) (2009) 1.03
PPAR-gamma in the Cardiovascular System. PPAR Res (2008) 1.01
Does peroxisome proliferator-activated receptor-gamma (PPAR gamma) protect from hypertension directly through effects in the vasculature? J Biol Chem (2010) 1.00
Dominant negative PPARγ promotes atherosclerosis, vascular dysfunction, and hypertension through distinct effects in endothelium and vascular muscle. Am J Physiol Regul Integr Comp Physiol (2013) 1.00
Relaxin causes selective outward remodeling of brain parenchymal arterioles via activation of peroxisome proliferator-activated receptor-γ. FASEB J (2011) 0.98
Decreased PPAR gamma expression compromises perigonadal-specific fat deposition and insulin sensitivity. Mol Endocrinol (2009) 0.95
'Striking the Right Balance' in Targeting PPARgamma in the Metabolic Syndrome: Novel Insights from Human Genetic Studies. PPAR Res (2007) 0.94
Defective peroxisomal proliferators activated receptor gamma activity due to dominant-negative mutation synergizes with hypertension to accelerate cardiac fibrosis in mice. Eur J Heart Fail (2009) 0.94
Genetic manipulations of PPARs: effects on obesity and metabolic disease. PPAR Res (2007) 0.94
Inhibitor of DNA binding 4 (ID4) regulation of adipocyte differentiation and adipose tissue formation in mice. J Biol Chem (2010) 0.94
Peroxisomal proliferator activated receptor-gamma deficiency in a Canadian kindred with familial partial lipodystrophy type 3 (FPLD3). BMC Med Genet (2006) 0.91
Rosiglitazone improves insulin sensitivity and baroreflex gain in rats with diet-induced obesity. J Pharmacol Exp Ther (2012) 0.88
Role of peroxisome proliferator-activated receptor-γ in vascular muscle in the cerebral circulation. Hypertension (2014) 0.86
Unbuckling lipodystrophy from insulin resistance and hypertension. J Clin Invest (2004) 0.85
Leptin therapy for partial lipodystrophy linked to a PPAR-gamma mutation. Clin Endocrinol (Oxf) (2007) 0.85
Genetic variations in peroxisome proliferator-activated receptor gamma expression affect blood pressure. Proc Natl Acad Sci U S A (2009) 0.84
Consequences of stopping and restarting leptin in an adolescent with lipodystrophy. Horm Res Paediatr (2012) 0.83
PPARs in the Renal Regulation of Systemic Blood Pressure. PPAR Res (2010) 0.82
PPARγ agonist beyond glucose lowering effect. Korean J Intern Med (2011) 0.81
Peroxisome proliferator-activated receptor-γ protects against vascular aging. Am J Physiol Regul Integr Comp Physiol (2012) 0.81
Effect of selective expression of dominant-negative PPARγ in pro-opiomelanocortin neurons on the control of energy balance. Physiol Genomics (2016) 0.80
Adipocyte (Pro)Renin-Receptor Deficiency Induces Lipodystrophy, Liver Steatosis and Increases Blood Pressure in Male Mice. Hypertension (2016) 0.78
Pparg-P465L mutation worsens hyperglycemia in Ins2-Akita female mice via adipose-specific insulin resistance and storage dysfunction. Diabetes (2010) 0.78
Carbon-nanoparticle-triggered acute lung inflammation and its resolution are not altered in PPARγ-defective (P465L) mice. Part Fibre Toxicol (2011) 0.78
Role of vascular smooth muscle PPARγ in regulating AT1 receptor signaling and angiotensin II-dependent hypertension. PLoS One (2014) 0.78
A clinical link between peroxisome proliferator-activated receptor γ and the renin-angiotensin system. Arterioscler Thromb Vasc Biol (2013) 0.78
Diuretics prevent thiazolidinedione-induced cardiac hypertrophy without compromising insulin-sensitizing effects in mice. Am J Pathol (2013) 0.76
Pro- and antiatherogenic effects of a dominant-negative P465L mutation of peroxisome proliferator-activated receptor-γ in apolipoprotein E-Null mice. Arterioscler Thromb Vasc Biol (2012) 0.76
Case-control study on peroxisome proliferator-activated receptor gamma polymorphism and interaction with HDL on essential hypertension in Chinese Han. Iran J Basic Med Sci (2015) 0.75
Is the Mouse a Good Model of Human PPARγ-Related Metabolic Diseases? Int J Mol Sci (2016) 0.75
PPARγ: no SirT, no service. Circ Res (2013) 0.75
Banting lecture 1988. Role of insulin resistance in human disease. Diabetes (1988) 33.22
Stimulation of adipogenesis in fibroblasts by PPAR gamma 2, a lipid-activated transcription factor. Cell (1994) 17.58
The fat-derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity. Nat Med (2001) 16.51
PPAR gamma is required for placental, cardiac, and adipose tissue development. Mol Cell (1999) 10.08
A Pro12Ala substitution in PPARgamma2 associated with decreased receptor activity, lower body mass index and improved insulin sensitivity. Nat Genet (1998) 8.02
PPAR gamma mediates high-fat diet-induced adipocyte hypertrophy and insulin resistance. Mol Cell (1999) 7.56
The mechanisms of action of PPARs. Annu Rev Med (2002) 6.71
Dominant negative mutations in human PPARgamma associated with severe insulin resistance, diabetes mellitus and hypertension. Nature (2000) 5.86
Generation of mice carrying a mutant apolipoprotein E gene inactivated by gene targeting in embryonic stem cells. Proc Natl Acad Sci U S A (1992) 5.75
Uncoupling protein-2 negatively regulates insulin secretion and is a major link between obesity, beta cell dysfunction, and type 2 diabetes. Cell (2001) 5.13
A noninvasive computerized tail-cuff system for measuring blood pressure in mice. Hypertension (1995) 4.08
Regulation of pancreatic beta-cell growth and survival by the serine/threonine protein kinase Akt1/PKBalpha. Nat Med (2001) 4.07
Insulin resistance and cardiovascular disease. J Clin Invest (2000) 4.05
Hypoinsulinaemia, glucose intolerance and diminished beta-cell size in S6K1-deficient mice. Nature (2001) 3.65
Targeting genes for self-excision in the germ line. Genes Dev (1999) 3.59
Prevalence of insulin resistance in metabolic disorders: the Bruneck Study. Diabetes (1998) 3.55
Efficacy and safety of troglitazone in the treatment of lipodystrophy syndromes. Ann Intern Med (2000) 3.44
The perils of portliness: causes and consequences of visceral adiposity. Diabetes (2000) 2.96
Redistribution of substrates to adipose tissue promotes obesity in mice with selective insulin resistance in muscle. J Clin Invest (2000) 2.75
Improved insulin-sensitivity in mice heterozygous for PPAR-gamma deficiency. J Clin Invest (2000) 2.67
Long-term telemetric measurement of cardiovascular parameters in awake mice: a physiological genomics tool. Physiol Genomics (2001) 2.58
Weight and blood pressure. Findings in hypertension screening of 1 million Americans. JAMA (1978) 2.54
Peroxisome proliferator-activated receptor gamma activators inhibit gene expression and migration in human vascular smooth muscle cells. Circ Res (1998) 2.39
Physiology and pathophysiology of the adipose tissue renin-angiotensin system. Hypertension (2000) 2.30
Human metabolic syndrome resulting from dominant-negative mutations in the nuclear receptor peroxisome proliferator-activated receptor-gamma. Diabetes (2003) 2.28
Peroxisome proliferator-activated receptor gamma plays a critical role in inhibition of cardiac hypertrophy in vitro and in vivo. Circulation (2002) 2.12
Adipose angiotensinogen is involved in adipose tissue growth and blood pressure regulation. FASEB J (2001) 2.09
PPARgamma activation in human endothelial cells increases plasminogen activator inhibitor type-1 expression: PPARgamma as a potential mediator in vascular disease. Arterioscler Thromb Vasc Biol (1999) 2.07
Obesity associated with a mutation in a genetic regulator of adipocyte differentiation. N Engl J Med (1998) 1.93
Pathophysiological role of angiotensin II type 2 receptor in cardiovascular and renal diseases. Circ Res (1999) 1.77
PPARG F388L, a transactivation-deficient mutant, in familial partial lipodystrophy. Diabetes (2002) 1.77
Impact of genetic background on development of hyperinsulinemia and diabetes in insulin receptor/insulin receptor substrate-1 double heterozygous mice. Diabetes (2003) 1.73
Effects of a thiazolidinedione compound on body fat and fat distribution of patients with type 2 diabetes. Diabetes Care (1999) 1.65
A novel heterozygous mutation in peroxisome proliferator-activated receptor-gamma gene in a patient with familial partial lipodystrophy. J Clin Endocrinol Metab (2002) 1.61
Differential gene expression between visceral and subcutaneous fat depots. Horm Metab Res (2003) 1.50
Depot-related gene expression in human subcutaneous and omental adipocytes. Diabetes (1998) 1.43
Digenic inheritance of severe insulin resistance in a human pedigree. Nat Genet (2002) 1.36
Adipose tissue-specific increase in angiotensinogen expression and secretion in the obese (fa/fa) Zucker rat. Am J Physiol Endocrinol Metab (2002) 1.30
Regulation of sodium balance and blood pressure by the AT(1A) receptor for angiotensin II. Hypertension (2000) 1.26
Expression of peroxisomal proliferator-activated receptors and retinoid X receptors in the kidney. Am J Physiol (1999) 1.22
Genetic modifiers of the insulin resistance phenotype in mice. Diabetes (2000) 1.14
Transcriptional regulation of the mouse uncoupling protein-2 gene. Double E-box motif is required for peroxisome proliferator-activated receptor-gamma-dependent activation. J Biol Chem (2001) 1.14
Peroxisome proliferator-activated receptor gamma activators downregulate angiotensin II type 1 receptor in vascular smooth muscle cells. Circulation (2000) 1.13
The thiazolidinedione rosiglitazone (BRL-49653) lowers blood pressure and protects against impairment of endothelial function in Zucker fatty rats. Diabetes (1999) 1.08
Enhancement of insulin sensitivity by troglitazone lowers blood pressure in diabetic hypertensives. Am J Hypertens (1995) 1.08
Pioglitazone attenuates hypertension and inhibits growth of renal arteriolar smooth muscle in rats. Am J Physiol (1993) 1.02
Insulin, insulin sensitivity and hypertension. J Hypertens (1990) 0.92
A single element in the phosphoenolpyruvate carboxykinase gene mediates thiazolidinedione action specifically in adipocytes. Biochimie (2001) 0.91
Endocrine regulation of energy metabolism by the skeleton. Cell (2007) 10.41
Mechanism by which fatty acids inhibit insulin activation of insulin receptor substrate-1 (IRS-1)-associated phosphatidylinositol 3-kinase activity in muscle. J Biol Chem (2002) 9.76
Fibroblast growth factor 21 reverses hepatic steatosis, increases energy expenditure, and improves insulin sensitivity in diet-induced obese mice. Diabetes (2008) 5.62
Antineutrophil cytoplasmic autoantibodies specific for myeloperoxidase cause glomerulonephritis and vasculitis in mice. J Clin Invest (2002) 5.42
A stress signaling pathway in adipose tissue regulates hepatic insulin resistance. Science (2008) 5.28
Differential effects of interleukin-6 and -10 on skeletal muscle and liver insulin action in vivo. Diabetes (2004) 4.37
Angiotensin II causes hypertension and cardiac hypertrophy through its receptors in the kidney. Proc Natl Acad Sci U S A (2006) 4.10
Cardiac natriuretic peptides act via p38 MAPK to induce the brown fat thermogenic program in mouse and human adipocytes. J Clin Invest (2012) 4.01
Mouse models of diabetic nephropathy. J Am Soc Nephrol (2009) 3.74
Targeted inactivation of hepatic Abca1 causes profound hypoalphalipoproteinemia and kidney hypercatabolism of apoA-I. J Clin Invest (2005) 3.25
JNK expression by macrophages promotes obesity-induced insulin resistance and inflammation. Science (2012) 3.12
PPARgamma coactivator 1beta/ERR ligand 1 is an ERR protein ligand, whose expression induces a high-energy expenditure and antagonizes obesity. Proc Natl Acad Sci U S A (2003) 2.89
Increased cellular free cholesterol in macrophage-specific Abca1 knock-out mice enhances pro-inflammatory response of macrophages. J Biol Chem (2008) 2.87
Prostacyclin protects against elevated blood pressure and cardiac fibrosis. Cell Metab (2005) 2.82
Dietary cholesterol, rather than liver steatosis, leads to hepatic inflammation in hyperlipidemic mouse models of nonalcoholic steatohepatitis. Hepatology (2008) 2.73
Distinct roles for the kidney and systemic tissues in blood pressure regulation by the renin-angiotensin system. J Clin Invest (2005) 2.59
FoxO1 expression in osteoblasts regulates glucose homeostasis through regulation of osteocalcin in mice. J Clin Invest (2009) 2.46
Txnip balances metabolic and growth signaling via PTEN disulfide reduction. Proc Natl Acad Sci U S A (2008) 2.41
Recipes for creating animal models of diabetic cardiovascular disease. Circ Res (2007) 2.34
Intermittent pressure overload triggers hypertrophy-independent cardiac dysfunction and vascular rarefaction. J Clin Invest (2006) 2.33
Unraveling the temporal pattern of diet-induced insulin resistance in individual organs and cardiac dysfunction in C57BL/6 mice. Diabetes (2005) 2.33
Fat cell-specific ablation of rictor in mice impairs insulin-regulated fat cell and whole-body glucose and lipid metabolism. Diabetes (2010) 2.30
Targeted deletion of the ileal bile acid transporter eliminates enterohepatic cycling of bile acids in mice. J Biol Chem (2003) 2.26
Prevention of steatosis by hepatic JNK1. Cell Metab (2009) 2.20
Tamm-Horsfall protein knockout mice are more prone to urinary tract infection: rapid communication. Kidney Int (2004) 2.17
The sympathetic tone mediates leptin's inhibition of insulin secretion by modulating osteocalcin bioactivity. J Cell Biol (2008) 2.14
Inactivation of fatty acid transport protein 1 prevents fat-induced insulin resistance in skeletal muscle. J Clin Invest (2004) 2.12
Molecular phenotyping for analyzing subtle genetic effects in mice: application to an angiotensinogen gene titration. Proc Natl Acad Sci U S A (2002) 2.08
Interleukin-10 prevents diet-induced insulin resistance by attenuating macrophage and cytokine response in skeletal muscle. Diabetes (2009) 2.00
Harmful effects of increased LDLR expression in mice with human APOE*4 but not APOE*3. Arterioscler Thromb Vasc Biol (2003) 2.00
The role of natriuretic peptides in cardioprotection. Cardiovasc Res (2005) 2.00
The role of neutrophils in the induction of glomerulonephritis by anti-myeloperoxidase antibodies. Am J Pathol (2005) 1.97
Comparing adiposity profiles in three mouse models with altered GH signaling. Growth Horm IGF Res (2004) 1.96
Overexpression of uncoupling protein 3 in skeletal muscle protects against fat-induced insulin resistance. J Clin Invest (2007) 1.91
Liver-specific deletion of protein-tyrosine phosphatase 1B (PTP1B) improves metabolic syndrome and attenuates diet-induced endoplasmic reticulum stress. Diabetes (2008) 1.88
Failure to detect Plasmodium vivax in West and Central Africa by PCR species typing. Malar J (2008) 1.85
Mitochondrial glycerol-3-phosphate acyltransferase-deficient mice have reduced weight and liver triacylglycerol content and altered glycerolipid fatty acid composition. Mol Cell Biol (2002) 1.77
Lymphocyte responses exacerbate angiotensin II-dependent hypertension. Am J Physiol Regul Integr Comp Physiol (2010) 1.76
Mice lacking MAP kinase phosphatase-1 have enhanced MAP kinase activity and resistance to diet-induced obesity. Cell Metab (2006) 1.76
The transcription factor ATF4 regulates glucose metabolism in mice through its expression in osteoblasts. J Clin Invest (2009) 1.73
Role of Rho-kinase in regulation of insulin action and glucose homeostasis. Cell Metab (2005) 1.73
Uncoupling of inflammation and insulin resistance by NF-kappaB in transgenic mice through elevated energy expenditure. J Biol Chem (2009) 1.71
Stimulation of lymphocyte responses by angiotensin II promotes kidney injury in hypertension. Am J Physiol Renal Physiol (2008) 1.71
Regulation of gluconeogenesis by Krüppel-like factor 15. Cell Metab (2007) 1.71
Ren1c homozygous null mice are hypotensive and polyuric, but heterozygotes are indistinguishable from wild-type. J Am Soc Nephrol (2004) 1.71
Salt-sensitive blood pressure in mice with increased expression of aldosterone synthase. Hypertension (2007) 1.70
Vitamin C is dispensable for oxygen sensing in vivo. Blood (2011) 1.68
Limited geographical origin and global spread of sulfadoxine-resistant dhps alleles in Plasmodium falciparum populations. J Infect Dis (2011) 1.68
Long-term, efficient inhibition of microRNA function in mice using rAAV vectors. Nat Methods (2012) 1.67
Grp78 heterozygosity promotes adaptive unfolded protein response and attenuates diet-induced obesity and insulin resistance. Diabetes (2009) 1.67
Improved glucose homeostasis in mice with muscle-specific deletion of protein-tyrosine phosphatase 1B. Mol Cell Biol (2007) 1.66
Vulnerable atherosclerotic plaque morphology in apolipoprotein E-deficient mice unable to make ascorbic Acid. Circulation (2002) 1.66
CCR5 deficiency is not protective in the early stages of atherogenesis in apoE knockout mice. Atherosclerosis (2003) 1.63
Disturbed homeostasis in sodium-restricted mice heterozygous and homozygous for aldosterone synthase gene disruption. Hypertension (2006) 1.62
Genetic modulation of PPARgamma phosphorylation regulates insulin sensitivity. Dev Cell (2003) 1.60
Aldosterone deficiency and mineralocorticoid receptor antagonism prevent angiotensin II-induced cardiac, renal, and vascular injury. Kidney Int (2012) 1.60
Inflammation induced by RAW macrophages suppresses UCP1 mRNA induction via ERK activation in 10T1/2 adipocytes. Am J Physiol Cell Physiol (2013) 1.59
Regulation of metabolic responses by adipocyte/macrophage Fatty Acid-binding proteins in leptin-deficient mice. Diabetes (2006) 1.56
Comparison between surrogate indexes of insulin sensitivity and resistance and hyperinsulinemic euglycemic clamp estimates in mice. Am J Physiol Endocrinol Metab (2007) 1.55
Analysis of the incidence and clinical effect of the heterotopic ossification in a single-level cervical artificial disc replacement. Spine J (2010) 1.55
Interference with PPARgamma signaling causes cerebral vascular dysfunction, hypertrophy, and remodeling. Hypertension (2008) 1.55
KSR2 is an essential regulator of AMP kinase, energy expenditure, and insulin sensitivity. Cell Metab (2009) 1.53
Early cardiac hypertrophy in mice with impaired calmodulin regulation of cardiac muscle Ca release channel. J Clin Invest (2007) 1.53
High plasma brain natriuretic polypeptide level as a marker of risk for thromboembolism in patients with nonvalvular atrial fibrillation. Stroke (2002) 1.52
Genes contributing to prion pathogenesis. J Gen Virol (2008) 1.51
The melanocortin-3 receptor is required for entrainment to meal intake. J Neurosci (2008) 1.49
Endogenous production of lipoic acid is essential for mouse development. Mol Cell Biol (2005) 1.49
Oxytocin receptor-deficient mice developed late-onset obesity. Neuroreport (2008) 1.49
Farnesyl pyrophosphate regulates adipocyte functions as an endogenous PPARγ agonist. Biochem J (2011) 1.49
Fibrosis, not cell size, delineates beta-myosin heavy chain reexpression during cardiac hypertrophy and normal aging in vivo. Proc Natl Acad Sci U S A (2006) 1.48
Tissue inhibitor of metalloproteinase-3 deficiency inhibits blood pressure elevation and myocardial microvascular remodeling induced by chronic administration of Nomega-nitro-L-arginine methyl ester in mice. Hypertens Res (2007) 1.47
Diabetic nephropathy is markedly enhanced in mice lacking the bradykinin B2 receptor. Proc Natl Acad Sci U S A (2004) 1.45
Role of muscle c-Jun NH2-terminal kinase 1 in obesity-induced insulin resistance. Mol Cell Biol (2010) 1.42
The SHP-1 protein tyrosine phosphatase negatively modulates glucose homeostasis. Nat Med (2006) 1.42
Genes and environment: novel, functional polymorphism in the human cathepsin L (CTSL1) promoter disrupts a xenobiotic response element (XRE) to alter transcription and blood pressure. J Hypertens (2012) 1.41
Skeletal muscle-specific deletion of lipoprotein lipase enhances insulin signaling in skeletal muscle but causes insulin resistance in liver and other tissues. Diabetes (2008) 1.41
Glomerular type 1 angiotensin receptors augment kidney injury and inflammation in murine autoimmune nephritis. J Clin Invest (2009) 1.41
Early diet-induced non-alcoholic steatohepatitis in APOE2 knock-in mice and its prevention by fibrates. J Hepatol (2005) 1.40
Increased energy expenditure, dietary fat wasting, and resistance to diet-induced obesity in mice lacking renin. Cell Metab (2007) 1.39
Hidden Transection of Follicular Unit Extraction in Donor Site. Dermatol Surg (2016) 1.39
Senescence-associated phenotypes in Akita diabetic mice are enhanced by absence of bradykinin B2 receptors. J Clin Invest (2006) 1.38
Role of the hypothalamic-pituitary-thyroid axis in metabolic regulation by JNK1. Genes Dev (2010) 1.36
Cardiac-specific knock-out of lipoprotein lipase alters plasma lipoprotein triglyceride metabolism and cardiac gene expression. J Biol Chem (2004) 1.34
Cardiac-specific overexpression of peroxisome proliferator-activated receptor-alpha causes insulin resistance in heart and liver. Diabetes (2005) 1.33
Human apoE4-targeted replacement mice display synaptic deficits in the absence of neuropathology. Neurobiol Dis (2005) 1.32
Minireview: estrogen and mouse models of atherosclerosis. Endocrinology (2002) 1.31
Ligand-activated peroxisome proliferator-activated receptor-gamma protects against ischemic cerebral infarction and neuronal apoptosis by 14-3-3 epsilon upregulation. Circulation (2009) 1.30
Bradykinin B1 and B2 receptors both have protective roles in renal ischemia/reperfusion injury. Proc Natl Acad Sci U S A (2007) 1.30
Caveolin-3 knockout mice show increased adiposity and whole body insulin resistance, with ligand-induced insulin receptor instability in skeletal muscle. Am J Physiol Cell Physiol (2005) 1.29
A mouse model of sitosterolemia: absence of Abcg8/sterolin-2 results in failure to secrete biliary cholesterol. BMC Med (2004) 1.28
Contributions from self-renewal and trafficking to the uterine NK cell population of early pregnancy. J Immunol (2002) 1.26
Apolipoprotein E knock-out and knock-in mice: atherosclerosis, metabolic syndrome, and beyond. J Lipid Res (2008) 1.26